The Clinical Observation of Gemcitabine or Paclitaxel Combined with Cisplatin in the treatment of Advanced Patients with non-small-cell Lung Cancer

Objective:To estimate the efficacy, toxicity and side effects of the two combinations of gemcitabine cisplatin and paclitaxel cisplatin in the treatment of advanced patients with non-small cell lung cancer (NSCLC).Methods:62 advanced patients with NSCLC diagnosed by pathology or cytology were enrolled into two groups randomly, each group have 31 patients. The group A with 31 patients received gemcitabine 1 200 mg/m 2 on d 1,8 and cisplatin 80mg/m 2 in the first day; The group B with another 31 patients received paclitaxel 150 mg/m 2 in the first day and cisplatin 80mg/m 2 in the first day. Both regiments had 21-day cycle, i.e., three weeks repeated and the efficacy was estimated after 3 periods. Results:The efficacy with group A and B were 48.3%(15/31) and 51.1%(16/31), respectively. There was no significant difference (P0.05) between two groups from the view of accounting. The median ailment development time were 4.5 and 3.4 months for group A and B, respectively and there had some accounting difference (P0.05). The median survival time were 11 and 10.5 months and no significant difference appeared (P0.05). Finally the 1-year survival time were 45.2% for group A and 41.9% for group B and there were also no significant difference (P0.05). The Ⅲ-Ⅳ thromasthenia with group A was little higher than that of group B, but the Ⅲ-Ⅳ leucopeniano and alopecia with group A were apparently lower than that of group B.Conclusion:There were no significant difference with group A and B on efficacy, median survival time and 1-year survival time, but there had little advantage with group A on median ailment development time.